Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes : Thousand&1 and Thousand&2 studies. / Bahrami, Hashmat Sayed Zohori; Jørgensen, Peter Godsk; Hove, Jens Dahlgaard; Dixen, Ulrik; Biering-Sørensen, Tor; Rossing, Peter; Jensen, Magnus T.

In: European Heart Journal Cardiovascular Imaging, Vol. 24, No. 11, 2023, p. 1555-1562.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bahrami, HSZ, Jørgensen, PG, Hove, JD, Dixen, U, Biering-Sørensen, T, Rossing, P & Jensen, MT 2023, 'Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies', European Heart Journal Cardiovascular Imaging, vol. 24, no. 11, pp. 1555-1562. https://doi.org/10.1093/ehjci/jead178

APA

Bahrami, H. S. Z., Jørgensen, P. G., Hove, J. D., Dixen, U., Biering-Sørensen, T., Rossing, P., & Jensen, M. T. (2023). Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies. European Heart Journal Cardiovascular Imaging, 24(11), 1555-1562. https://doi.org/10.1093/ehjci/jead178

Vancouver

Bahrami HSZ, Jørgensen PG, Hove JD, Dixen U, Biering-Sørensen T, Rossing P et al. Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies. European Heart Journal Cardiovascular Imaging. 2023;24(11):1555-1562. https://doi.org/10.1093/ehjci/jead178

Author

Bahrami, Hashmat Sayed Zohori ; Jørgensen, Peter Godsk ; Hove, Jens Dahlgaard ; Dixen, Ulrik ; Biering-Sørensen, Tor ; Rossing, Peter ; Jensen, Magnus T. / Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes : Thousand&1 and Thousand&2 studies. In: European Heart Journal Cardiovascular Imaging. 2023 ; Vol. 24, No. 11. pp. 1555-1562.

Bibtex

@article{d5b31a5c579c4e0ea1f7e4722cc1626b,
title = "Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies",
abstract = "AIMS: Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in type 1 (T1D) and type 2 diabetes (T2D). Despite diabetes affects the myocardium, risk prediction models do not include myocardial function parameters. Myocardial performance index (MPI) reflects left ventricular function. The prognostic value of MPI has not been evaluated in large-scale diabetes populations.METHODS AND RESULTS: We evaluated two prospective cohort studies: Thousand&1 (1093 individuals with T1D) and Thousand&2 (1030 individuals with T2D). Clinical data, including echocardiography, were collected at baseline. We collected follow-up data from national registries. We defined major adverse cardiovascular events (MACE) as incident events of hospital admission for acute coronary syndrome, heart failure, stroke, or all-cause mortality. For included individuals (56% male, 54 ± 15 years, MPI 0.51 ± 0.1, 63% T1D), follow-up was 100% after median of 5.3 years (range: 4.8-6.3). MPI was associated with MACE (HR 1.2, 95%CI 1.0-1.3, P = 0.012, per 0.10-unit increase) and heart failure (HR 1.3, 95%CI 1.1-1.6, P = 0.005, per 0.10-unit increase) after adjusting for clinical and echocardiographic variables. MPI predicted MACE and heart failure better in T1D than T2D (P = 0.031 for interaction). MPI added discriminatory power to the Steno T1 Risk Engine, based on clinical characteristics, in predicting MACE [area under the curve (AUC) from 0.77 to 0.79, P = 0.030] and heart failure (AUC from 0.77 to 0.83, P = 0.009) in T1D.CONCLUSION: MPI is independently associated with MACE and heart failure in T1D but not T2D and improves prediction in T1D. Echocardiographic assessment in T1D may enhance risk prediction.",
keywords = "Humans, Male, Female, Prognosis, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus, Type 1/complications, Prospective Studies, Heart Failure/etiology, Risk Factors",
author = "Bahrami, {Hashmat Sayed Zohori} and J{\o}rgensen, {Peter Godsk} and Hove, {Jens Dahlgaard} and Ulrik Dixen and Tor Biering-S{\o}rensen and Peter Rossing and Jensen, {Magnus T.}",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2023",
doi = "10.1093/ehjci/jead178",
language = "English",
volume = "24",
pages = "1555--1562",
journal = "European Heart Journal Cardiovascular Imaging",
issn = "2047-2404",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes

T2 - Thousand&1 and Thousand&2 studies

AU - Bahrami, Hashmat Sayed Zohori

AU - Jørgensen, Peter Godsk

AU - Hove, Jens Dahlgaard

AU - Dixen, Ulrik

AU - Biering-Sørensen, Tor

AU - Rossing, Peter

AU - Jensen, Magnus T.

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2023

Y1 - 2023

N2 - AIMS: Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in type 1 (T1D) and type 2 diabetes (T2D). Despite diabetes affects the myocardium, risk prediction models do not include myocardial function parameters. Myocardial performance index (MPI) reflects left ventricular function. The prognostic value of MPI has not been evaluated in large-scale diabetes populations.METHODS AND RESULTS: We evaluated two prospective cohort studies: Thousand&1 (1093 individuals with T1D) and Thousand&2 (1030 individuals with T2D). Clinical data, including echocardiography, were collected at baseline. We collected follow-up data from national registries. We defined major adverse cardiovascular events (MACE) as incident events of hospital admission for acute coronary syndrome, heart failure, stroke, or all-cause mortality. For included individuals (56% male, 54 ± 15 years, MPI 0.51 ± 0.1, 63% T1D), follow-up was 100% after median of 5.3 years (range: 4.8-6.3). MPI was associated with MACE (HR 1.2, 95%CI 1.0-1.3, P = 0.012, per 0.10-unit increase) and heart failure (HR 1.3, 95%CI 1.1-1.6, P = 0.005, per 0.10-unit increase) after adjusting for clinical and echocardiographic variables. MPI predicted MACE and heart failure better in T1D than T2D (P = 0.031 for interaction). MPI added discriminatory power to the Steno T1 Risk Engine, based on clinical characteristics, in predicting MACE [area under the curve (AUC) from 0.77 to 0.79, P = 0.030] and heart failure (AUC from 0.77 to 0.83, P = 0.009) in T1D.CONCLUSION: MPI is independently associated with MACE and heart failure in T1D but not T2D and improves prediction in T1D. Echocardiographic assessment in T1D may enhance risk prediction.

AB - AIMS: Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in type 1 (T1D) and type 2 diabetes (T2D). Despite diabetes affects the myocardium, risk prediction models do not include myocardial function parameters. Myocardial performance index (MPI) reflects left ventricular function. The prognostic value of MPI has not been evaluated in large-scale diabetes populations.METHODS AND RESULTS: We evaluated two prospective cohort studies: Thousand&1 (1093 individuals with T1D) and Thousand&2 (1030 individuals with T2D). Clinical data, including echocardiography, were collected at baseline. We collected follow-up data from national registries. We defined major adverse cardiovascular events (MACE) as incident events of hospital admission for acute coronary syndrome, heart failure, stroke, or all-cause mortality. For included individuals (56% male, 54 ± 15 years, MPI 0.51 ± 0.1, 63% T1D), follow-up was 100% after median of 5.3 years (range: 4.8-6.3). MPI was associated with MACE (HR 1.2, 95%CI 1.0-1.3, P = 0.012, per 0.10-unit increase) and heart failure (HR 1.3, 95%CI 1.1-1.6, P = 0.005, per 0.10-unit increase) after adjusting for clinical and echocardiographic variables. MPI predicted MACE and heart failure better in T1D than T2D (P = 0.031 for interaction). MPI added discriminatory power to the Steno T1 Risk Engine, based on clinical characteristics, in predicting MACE [area under the curve (AUC) from 0.77 to 0.79, P = 0.030] and heart failure (AUC from 0.77 to 0.83, P = 0.009) in T1D.CONCLUSION: MPI is independently associated with MACE and heart failure in T1D but not T2D and improves prediction in T1D. Echocardiographic assessment in T1D may enhance risk prediction.

KW - Humans

KW - Male

KW - Female

KW - Prognosis

KW - Diabetes Mellitus, Type 2/complications

KW - Diabetes Mellitus, Type 1/complications

KW - Prospective Studies

KW - Heart Failure/etiology

KW - Risk Factors

U2 - 10.1093/ehjci/jead178

DO - 10.1093/ehjci/jead178

M3 - Journal article

C2 - 37638773

VL - 24

SP - 1555

EP - 1562

JO - European Heart Journal Cardiovascular Imaging

JF - European Heart Journal Cardiovascular Imaging

SN - 2047-2404

IS - 11

ER -

ID: 371866254